Dyadic International

DYAI

시가총액 US$1647만

Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private placement of warrants to the same investor.

Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript

JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing platform expansion.

JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins.

JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended Jun 30, 2026 and host a corporate update conference call on Wednesday, August 12, 2026.

JUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, today announced that, within approximately 15 days of receiving the plasmids, it developed stable pools of C1 cell lines and manufactured and initially purified two Scripps-designed Bundibugyo ebolavirus recombinant protein antigens.

JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced that Nasdaq has confirmed that the Company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b).

JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food, nutrition, bio-industrial and biopharmaceutical markets, today announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing.

Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dyadic's Ebola preparedness work highlights C1's potentia